ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PSMA/STEAP1 Antibody-drug Conjugate ABBV-969

In AbbVie’s pipeline, PSMA,STEAP1. Its studies are mostly in Prostatic Neoplasms, led by AbbVie.

Furthest: phase 1, since Mar 13, 20241 company-led study, 1 open or runningNext primary completion: May 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie11 open or runningphase 1since Mar 13, 2024Mar 13, 2024May 2027phase 1 · NCT06318273
  • Named in AbbVie’s own pipeline as ABBV-969, phase 1, as of Jul 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 13, 2024First study: phase 1 study in Metastatic Castration-Resistant Prostate CancerFirst studyNCT06318273 · 152 enrolled · United States, Australia, Canada and more

Ahead

  1. May 2027Primary completion: phase 1 study in Metastatic Castration-Resistant Prostate CancerNCT06318273

TargetBeta

“PSMA,STEAP1”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06318273Metastatic Castration-Resistant Prostate Cancer · United States, Australia, Canada and more1Active, not recruitingMay 2027152

How it is read

Names in the registry

  • “ABBV-969”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.